HK1160638A1 - Hydroxylated cyclopenta[d]pyrimidines as akt protein kinase inhibitors akt [d] - Google Patents

Hydroxylated cyclopenta[d]pyrimidines as akt protein kinase inhibitors akt [d]

Info

Publication number
HK1160638A1
HK1160638A1 HK12100670.3A HK12100670A HK1160638A1 HK 1160638 A1 HK1160638 A1 HK 1160638A1 HK 12100670 A HK12100670 A HK 12100670A HK 1160638 A1 HK1160638 A1 HK 1160638A1
Authority
HK
Hong Kong
Prior art keywords
akt
pyrimidines
protein kinase
kinase inhibitors
cyclopenta
Prior art date
Application number
HK12100670.3A
Other languages
English (en)
Chinese (zh)
Inventor
Ian S Mitchell
James F Blake
Rui Xu
Nicholas C Kallan
Dengming Xiao
Keith Lee Spencer
Josef R Bencsik
Jun Liang
Brian Safina
Birong Zhang
Christine Chabot
Steven Do
Eli W Wallace
Anna L Banka
Stephen T Schlachter
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38686743&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1160638(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of HK1160638A1 publication Critical patent/HK1160638A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pregnancy & Childbirth (AREA)
  • AIDS & HIV (AREA)
  • Psychology (AREA)
HK12100670.3A 2006-07-06 2009-06-25 Hydroxylated cyclopenta[d]pyrimidines as akt protein kinase inhibitors akt [d] HK1160638A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US81871806P 2006-07-06 2006-07-06

Publications (1)

Publication Number Publication Date
HK1160638A1 true HK1160638A1 (en) 2012-08-10

Family

ID=38686743

Family Applications (3)

Application Number Title Priority Date Filing Date
HK09105739.6A HK1126768A1 (en) 2006-07-06 2009-06-25 Hydroxylated and methoxylated cyclopenta [d] pyrimidines as akt protein kinase inhibitors
HK12100670.3A HK1160638A1 (en) 2006-07-06 2009-06-25 Hydroxylated cyclopenta[d]pyrimidines as akt protein kinase inhibitors akt [d]
HK12100669.6A HK1160134A1 (en) 2006-07-06 2009-06-25 Hydroxylated cyclopenta[d]pyrimidines as akt protein kinase inhibitors akt [d]

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK09105739.6A HK1126768A1 (en) 2006-07-06 2009-06-25 Hydroxylated and methoxylated cyclopenta [d] pyrimidines as akt protein kinase inhibitors

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK12100669.6A HK1160134A1 (en) 2006-07-06 2009-06-25 Hydroxylated cyclopenta[d]pyrimidines as akt protein kinase inhibitors akt [d]

Country Status (35)

Country Link
EP (4) EP2966065A3 (pt)
JP (4) JP5266216B2 (pt)
KR (5) KR101495408B1 (pt)
CN (2) CN101578273B (pt)
AR (3) AR061842A1 (pt)
AT (1) ATE524447T1 (pt)
AU (1) AU2007269060B2 (pt)
BR (3) BR122013028005B8 (pt)
CA (2) CA2656622C (pt)
CL (1) CL2007001993A1 (pt)
CO (1) CO6150161A2 (pt)
CR (1) CR10600A (pt)
CY (1) CY1112117T1 (pt)
DK (2) DK2402325T3 (pt)
ES (3) ES2554228T3 (pt)
HK (3) HK1126768A1 (pt)
HR (1) HRP20110908T1 (pt)
HU (1) HUE026237T2 (pt)
IL (2) IL196028A (pt)
IN (1) IN2014KN02886A (pt)
MA (1) MA31655B1 (pt)
MX (4) MX366319B (pt)
MY (1) MY147364A (pt)
NO (1) NO342346B1 (pt)
NZ (3) NZ610633A (pt)
PL (2) PL2049501T3 (pt)
PT (1) PT2049501E (pt)
RS (1) RS52212B (pt)
RU (2) RU2478632C2 (pt)
SG (4) SG184706A1 (pt)
SI (2) SI2402325T1 (pt)
TW (2) TW201332994A (pt)
UA (1) UA95641C2 (pt)
WO (1) WO2008006040A1 (pt)
ZA (1) ZA200900070B (pt)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA95641C2 (en) * 2006-07-06 2011-08-25 Эррей Биофарма Инк. Hydroxylated cyclopenta [d] pyrimidines as akt protein kinase inhibitors
ATE532789T1 (de) * 2006-07-06 2011-11-15 Array Biopharma Inc Dihydrothienopyrimidine als akt-proteinkinase- inhibitoren
US8329701B2 (en) 2006-07-06 2012-12-11 Array Biopharma Inc. Dihydrofuro pyrimidines as AKT protein kinase inhibitors
WO2008006032A1 (en) 2006-07-06 2008-01-10 Array Biopharma Inc. Cyclopenta [d] pyrimidines as akt protein kinase inhibitors
US8063050B2 (en) 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
WO2008115511A1 (en) 2007-03-20 2008-09-25 Peak Biosciences, Inc. Method for therapeutic administration of radionucleosides
US9409886B2 (en) 2007-07-05 2016-08-09 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
EP2173723B3 (en) 2007-07-05 2014-11-19 Array Biopharma Inc. Pyrimidyl cyclopentanes as akt protein kinase inhibitors
US8846683B2 (en) 2007-07-05 2014-09-30 Array Biopharma, Inc. Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
RU2486181C2 (ru) 2007-07-05 2013-06-27 Эррэй Биофарма Инк. Пиримидилциклопентаны как ингибиторы акт-протеинкиназ
WO2009089454A1 (en) 2008-01-09 2009-07-16 Array Biopharma Inc. Pyrimidyl cyclopentanes as akt protein kinase inhibitors
CN104876921A (zh) 2008-01-09 2015-09-02 阵列生物制药公司 作为AKT蛋白激酶抑制剂的5H-环戊二烯并[d]嘧啶
ES2422733T3 (es) 2008-01-09 2013-09-13 Array Biopharma Inc Pirimidilciclopentanos hidroxilados como inhibidores de proteínas cinasas AKT
AU2009204019B2 (en) 2008-01-09 2014-02-20 Array Biopharma Inc. Hydroxylated pyrimidyl cyclopentane as AKT protein kinase inhibitor
CN103403161A (zh) * 2010-12-23 2013-11-20 基因泰克公司 用于治疗新生物的自噬诱导剂和抑制剂组合疗法
CN103857395A (zh) 2011-04-01 2014-06-11 基因泰克公司 Akt抑制剂化合物和阿比特龙的组合及使用方法
JP6147246B2 (ja) 2011-04-01 2017-06-14 ジェネンテック， インコーポレイテッド Ａｋｔ及びｍｅｋ阻害剤化合物の組み合わせ、及び使用方法
ES2768081T3 (es) * 2011-04-01 2020-06-19 Genentech Inc Biomarcadores para predecir sensibilidad a tratamientos para el cáncer
WO2013173736A1 (en) 2012-05-17 2013-11-21 Array Biopharma Inc. Process for making hydroxylated cyclopentylpyrimidine compounds
DK2858989T3 (da) * 2012-05-17 2020-06-02 Genentech Inc Amorf form af en AKT-hæmmende pyrimidinyl-cyclopentan-forbindelse, sammensætninger deraf og fremgangsmåder dertil
CN104471070B (zh) * 2012-05-17 2018-09-25 基因泰克公司 制备羟基化环戊并嘧啶化合物和其盐的方法
JP6284928B2 (ja) 2012-05-17 2018-02-28 アレイ バイオファーマ、インコーポレイテッド ヒドロキシル化シクロペンチルピリミジン化合物を作製するためのプロセス
RU2643146C2 (ru) * 2012-05-17 2018-01-31 Дженентек, Инк. Способ получения аминокислотных соединений
WO2014068070A1 (en) 2012-10-31 2014-05-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for preventing antiphospholipid syndrome (aps)
EP2928488A1 (en) * 2012-12-07 2015-10-14 The General Hospital Corporation Combinations of a pi3k/akt inhibitor compound with an her3/egfr inhibitor compound and use thereof in the treatment of a hyperproliferative disorder
JP6340162B2 (ja) 2012-12-20 2018-06-06 日東電工株式会社 アポトーシス誘導剤
CN112898210A (zh) 2013-11-15 2021-06-04 豪夫迈·罗氏有限公司 用于制备嘧啶基环戊烷化合物的方法
CN107001287B (zh) 2014-09-26 2020-09-04 豪夫迈·罗氏有限公司 用于制备(环戊并[d]嘧啶-4-基)哌嗪化合物的方法
KR20230124110A (ko) 2016-08-10 2023-08-24 에프. 호프만-라 로슈 아게 Akt 단백질 키나아제 저해제를 포함하는 약학 조성물
CA3092677A1 (en) * 2018-03-06 2019-09-12 Icahn School Of Medicine At Mount Sinai Serine threonine kinase (akt) degradation / disruption compounds and methods of use
US11701356B2 (en) 2018-12-19 2023-07-18 Genentech, Inc. Treatment of breast cancer using combination therapies comprising an AKT inhibitor, a taxane, and a PD-L1 inhibitor
EP3903828A4 (en) 2018-12-21 2022-10-05 Daiichi Sankyo Company, Limited COMBINATION OF AN ANTIBODY-DRUG CONJUGATE AND A KINASE INHIBITOR
WO2020156437A1 (zh) 2019-01-29 2020-08-06 南京正大天晴制药有限公司 Akt抑制剂
EP3946330A1 (en) 2019-03-29 2022-02-09 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of keloid, hypertrophic scars and/or hyperpigmentation disorders
CN113645972A (zh) * 2019-04-09 2021-11-12 达纳-法伯癌症研究所有限公司 通过atp-竞争性akt抑制剂gdc-0068与e3连接酶配体的接合降解akt及使用方法
EP4165026A1 (en) 2020-06-16 2023-04-19 F. Hoffmann-La Roche AG Process for making hydroxylated cyclopentylpyrimidine compounds
WO2022017449A1 (zh) 2020-07-22 2022-01-27 南京正大天晴制药有限公司 一种二氢吡啶并[2,3-d]嘧啶酮衍生物的盐、其制备方法及用途
TWI750905B (zh) * 2020-11-19 2021-12-21 財團法人國家衛生研究院 噻唑化合物作為蛋白質激酶抑制劑
KR20230035773A (ko) * 2021-09-06 2023-03-14 연세대학교 산학협력단 Akt 신호경로 억제제를 유효성분으로 포함하는 아토피피부염의 예방 또는 치료용 조성물
WO2023043869A1 (en) * 2021-09-15 2023-03-23 Teva Pharmaceuticals International Gmbh Solid state forms of ipatasertib citrate
CN113788834B (zh) * 2021-09-18 2022-11-29 河南奥思恩医药科技有限公司 2,4-二氯-6,7-二氢-5H-吡咯并[3,4-d]嘧啶盐酸盐的制备方法
WO2023109540A1 (zh) * 2021-12-17 2023-06-22 中国医药研究开发中心有限公司 具有akt激酶抑制活性的杂环化合物及其制备方法和医药用途
WO2023187037A1 (en) 2022-03-31 2023-10-05 Astrazeneca Ab Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors in combination with an akt inhibitor for the treatment of cancer
WO2024083716A1 (en) 2022-10-17 2024-04-25 Astrazeneca Ab Combinations of a serd for the treatment of cancer
WO2024100236A1 (en) 2022-11-11 2024-05-16 Astrazeneca Ab Combination therapies for the treatment of cancer

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
NL7112938A (pt) * 1970-09-30 1972-04-05
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
ATE257470T1 (de) * 1997-01-08 2004-01-15 Hoffmann La Roche Tricyclische benz(e)isoindole und benz(h)isochinoline
ES2152902B1 (es) * 1999-07-27 2001-08-16 Medichem Sa Procedimiento de obtencion de venlafaxina
HU228668B1 (hu) * 2000-08-18 2013-05-28 Millennium Pharmaceuticals Kináz inhibitor kinazolin-származékok és az ezeket tartalmazó gyógyszerkészítmények
DE60120193T2 (de) * 2000-09-15 2007-03-29 Vertex Pharmaceuticals Inc., Cambridge Pyrazolverbindungen als protein-kinasehemmer
US7101905B2 (en) * 2001-03-30 2006-09-05 King Pharmaceuticals Research & Development, Inc. Pharmaceutically active compounds and methods of use
ATE424388T1 (de) * 2001-12-06 2009-03-15 Merck & Co Inc Mitotische kinesinhemmer
WO2003062225A1 (en) * 2002-01-23 2003-07-31 Bayer Pharmaceuticals Corporation Pyrimidine derivatives as rho-kinase inhibitors
TW200306819A (en) * 2002-01-25 2003-12-01 Vertex Pharma Indazole compounds useful as protein kinase inhibitors
NZ547327A (en) * 2003-11-21 2009-08-28 Array Biopharma Inc AKT protein kinase inhibitors
EP1751133B1 (en) * 2004-04-28 2010-04-14 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of rock and other protein kinases
WO2005113762A1 (en) 2004-05-18 2005-12-01 Pfizer Products Inc. CRYSTAL STRUCTURE OF PROTEIN KINASE B-α (AKT-1) AND USES THEREOF
CA2600745A1 (en) * 2005-03-03 2006-09-08 The Burnham Institute For Medical Research Screening methods for protein kinase b inhibitors employing virtual docking approaches and compounds and compositions discovered thereby
UA95641C2 (en) * 2006-07-06 2011-08-25 Эррей Биофарма Инк. Hydroxylated cyclopenta [d] pyrimidines as akt protein kinase inhibitors
WO2008006032A1 (en) * 2006-07-06 2008-01-10 Array Biopharma Inc. Cyclopenta [d] pyrimidines as akt protein kinase inhibitors
ATE532789T1 (de) * 2006-07-06 2011-11-15 Array Biopharma Inc Dihydrothienopyrimidine als akt-proteinkinase- inhibitoren

Also Published As

Publication number Publication date
CO6150161A2 (es) 2010-04-20
BR122013028012B8 (pt) 2021-05-25
ES2554228T3 (es) 2015-12-17
EP2399909A1 (en) 2011-12-28
NO342346B1 (no) 2018-05-07
TWI402266B (zh) 2013-07-21
IL196028A (en) 2017-02-28
SG188905A1 (en) 2013-04-30
KR101495408B1 (ko) 2015-02-25
EP2402325A2 (en) 2012-01-04
UA95641C2 (en) 2011-08-25
KR20130029364A (ko) 2013-03-22
HK1126768A1 (en) 2009-09-11
MX2008016202A (es) 2009-02-11
AR093810A2 (es) 2015-06-24
MX2019008117A (es) 2019-09-04
CA2656622A1 (en) 2008-01-10
SG185980A1 (en) 2012-12-28
IN2014KN02886A (pt) 2015-05-08
PL2402325T3 (pl) 2016-01-29
KR20150051240A (ko) 2015-05-11
EP2966065A2 (en) 2016-01-13
BRPI0713923B8 (pt) 2021-05-25
NZ610633A (en) 2014-12-24
HK1160134A1 (en) 2012-08-10
CA2836316A1 (en) 2008-01-10
KR20140093291A (ko) 2014-07-25
EP2402325B1 (en) 2015-08-26
RU2012155606A (ru) 2014-06-27
JP2013091670A (ja) 2013-05-16
BRPI0713923B1 (pt) 2020-09-29
EP2399909B1 (en) 2015-08-26
ES2554252T3 (es) 2015-12-17
CL2007001993A1 (es) 2008-06-20
NZ597647A (en) 2013-08-30
TW200817373A (en) 2008-04-16
TW201332994A (zh) 2013-08-16
SG10201802127UA (en) 2018-04-27
ES2372774T3 (es) 2012-01-26
ATE524447T1 (de) 2011-09-15
SG184706A1 (en) 2012-10-30
RS52212B (en) 2012-10-31
JP2014231530A (ja) 2014-12-11
RU2478632C2 (ru) 2013-04-10
BR122013028012B1 (pt) 2021-04-06
JP5266216B2 (ja) 2013-08-21
DK2402325T3 (en) 2015-12-07
BR122013028005B8 (pt) 2021-05-25
KR101178672B1 (ko) 2012-09-07
MA31655B1 (fr) 2010-09-01
AR061842A1 (es) 2008-09-24
NZ573732A (en) 2012-03-30
MX366319B (es) 2019-07-05
BR122013028005B1 (pt) 2021-04-06
AU2007269060A1 (en) 2008-01-10
KR20090030333A (ko) 2009-03-24
HRP20110908T1 (hr) 2012-02-29
CY1112117T1 (el) 2015-11-04
RU2009103900A (ru) 2010-08-20
SI2049501T1 (sl) 2012-01-31
SI2402325T1 (sl) 2015-12-31
ZA200900070B (en) 2010-03-31
EP2049501B1 (en) 2011-09-14
AR109424A2 (es) 2018-11-28
BRPI0713923A2 (pt) 2013-07-02
JP2013177470A (ja) 2013-09-09
MX337843B (es) 2016-03-22
NO20090581L (no) 2009-04-06
EP2966065A3 (en) 2016-03-02
JP5836294B2 (ja) 2015-12-24
KR20130141717A (ko) 2013-12-26
KR101578877B1 (ko) 2016-02-22
PT2049501E (pt) 2011-12-30
HUE026237T2 (en) 2016-06-28
EP2402325A3 (en) 2012-06-13
EP2049501A1 (en) 2009-04-22
CA2656622C (en) 2017-09-12
AU2007269060B2 (en) 2014-02-20
PL2049501T3 (pl) 2012-02-29
CR10600A (es) 2009-02-20
CN102816124A (zh) 2012-12-12
IL241705A0 (en) 2015-11-30
MY147364A (en) 2012-11-30
JP2009542723A (ja) 2009-12-03
DK2049501T3 (da) 2011-12-12
CN101578273B (zh) 2012-11-14
IL196028A0 (en) 2009-09-01
WO2008006040A1 (en) 2008-01-10
CN101578273A (zh) 2009-11-11

Similar Documents

Publication Publication Date Title
HK1160134A1 (en) Hydroxylated cyclopenta[d]pyrimidines as akt protein kinase inhibitors akt [d]
IL196051A0 (en) Cyclopenta [d] pyrimidines as akt protein kinase inhibitors
HK1150605A1 (en) 5h-cyclopenta[d]pyrimidines as akt protein kinase inhibitors
EP2497470B8 (en) Imidazotriazines and imidazopyrimidines as kinase inhibitors
ZA200809796B (en) Pyrazolo [1,5-A]pyrimidines as CDK inhibitors
HK1147255A1 (en) Pyrimidyl cyclopentanes as akt protein kinase inhibitors
EP2240483B8 (en) Pyrimidyl cyclopentanes as akt protein kinase inhibitors
ZA200806313B (en) Pyrrolo [3,2-c]pyridine-4-one 2-indolinone protein kinase inhibitors
AU2005310968A1 (en) Bicyclic amides as kinase inhibitors
HK1146042A1 (en) Pyrimidine derivatives as protein kinase inhibitors
HK1158947A1 (en) Macrocyclic pyrimidines as protein kinase inhibitors
IL195005A0 (en) Inhibitors of akt (protein kinase b)
HK1208701A1 (en) Means for inhibiting the expression of protein kinase
IL199378A0 (en) 2-substituted-6-heterocyclic pyrimidone derivatives as tau protein kinase 1 inhibitors
HK1149269A1 (en) Hydroxylated pyrimidyl cyclopentane as akt protein kinase inhibitor
ZA201004769B (en) Hydroxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors
IL194491A0 (en) Thiazolyldihydroindazole derivatives as protein kinase inhibitors
ZA200810573B (en) Substituted 3-cyanopyridines as protein kinase inhibitors
ZA200809545B (en) Inhibitors of Akt (protein kinase B)
AU2014201698B2 (en) Means for inhibiting the expression of protein kinase 3